Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Julphar
Federal Trade Commission
Farmers Insurance
Express Scripts
Merck
McKesson
Accenture
Citi

Generated: October 19, 2018

DrugPatentWatch Database Preview

Wyeth Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for WYETH PHARMS INC, and what generic alternatives to WYETH PHARMS INC drugs are available?

WYETH PHARMS INC has eighteen approved drugs.

There are three US patents protecting WYETH PHARMS INC drugs.

Summary for Wyeth Pharms Inc
US Patents:3
Tradenames:19
Ingredients:14
NDAs:18

Drugs and US Patents for Wyeth Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Pharms Inc PIPRACIL piperacillin sodium INJECTABLE;INJECTION 050545-004 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Sign Up ➤ Sign Up
Wyeth Pharms Inc PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-001 Feb 29, 2008 AB RX Yes Yes 8,269,040 ➤ Sign Up Y ➤ Sign Up
Wyeth Pharms Inc PIPRACIL piperacillin sodium INJECTABLE;INJECTION 050545-003 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Sign Up ➤ Sign Up
Wyeth Pharms Inc ORUVAIL ketoprofen CAPSULE, EXTENDED RELEASE;ORAL 019816-001 Sep 24, 1993 DISCN Yes No ➤ Sign Up ➤ Sign Up
Wyeth Pharms Inc LODINE etodolac TABLET;ORAL 018922-005 Jun 28, 1996 DISCN Yes No ➤ Sign Up ➤ Sign Up
Wyeth Pharms Inc PHOSPHOLINE IODIDE echothiophate iodide FOR SOLUTION;OPHTHALMIC 011963-003 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Wyeth Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Wyeth Pharms Inc EFFEXOR venlafaxine hydrochloride TABLET;ORAL 020151-003 Dec 28, 1993 6,274,171 ➤ Sign Up
Wyeth Pharms Inc NORPLANT SYSTEM IN PLASTIC CONTAINER levonorgestrel IMPLANT;IMPLANTATION 020088-001 Dec 10, 1990 3,850,911 ➤ Sign Up
Wyeth Pharms Inc EFFEXOR venlafaxine hydrochloride TABLET;ORAL 020151-004 Dec 28, 1993 6,274,171 ➤ Sign Up
Wyeth Pharms Inc EFFEXOR venlafaxine hydrochloride TABLET;ORAL 020151-001 Dec 28, 1993 4,535,186*PED ➤ Sign Up
Wyeth Pharms Inc LODINE XL etodolac TABLET, EXTENDED RELEASE;ORAL 020584-003 Jan 20, 1998 4,966,768*PED ➤ Sign Up
Wyeth Pharms Inc MYLOTARG gemtuzumab ozogamicin INJECTABLE;INJECTION 021174-001 May 17, 2000 5,773,001 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for WYETH PHARMS INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Tablets 50 mg and 100 mg ➤ Subscribe 2012-02-29
➤ Subscribe Tablets 25 mg, 37.5 mg, 50 mg, 75 mg and 100 mg ➤ Subscribe 2005-11-03
➤ Subscribe Extended-release Tablets 25 mg ➤ Subscribe 2015-05-08
➤ Subscribe Tablets 0.09 mg/0.02 mg ➤ Subscribe 2007-10-05

Supplementary Protection Certificates for Wyeth Pharms Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
156 Luxembourg ➤ Sign Up PRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211
13/055 Ireland ➤ Sign Up PRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. QUINIDINE SULPHATE AND IN PARTICULAR QUINIDINE SULPHATE DIHYDRATE, PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/833 20130624
00221 Netherlands ➤ Sign Up PRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307
2015000093 Germany ➤ Sign Up PRODUCT NAME: LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 87675.00.00 20150720; FIRST REGISTRATION: SLOWAKEI 17/0017/15-S 20150129
0814 Netherlands ➤ Sign Up PRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211
00095 Netherlands ➤ Sign Up PRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Fish and Richardson
Express Scripts
Boehringer Ingelheim
Farmers Insurance
Healthtrust
Baxter
Cipla
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.